Merck & Co., Inc.MRK

時価総額
$2486.2億
PER
研究開発型バイオ医薬品・ワクチン・動物用製品の世界最大手。がん免疫療法やワクチン、デジタル獣医保健ソリューションを展開。2024年7月に眼科バイオ企業を約12億ドルで買収。米国・欧州・中国や新興市場を中心に展開。
2010/122011/122012/122013/122014/122015/122016/122017/122018/122019/122020/122021/122022/122023/122024/12
売上高45,98748,04747,26744,03342,23739,49839,80740,12242,29446,84047,99448,70459,28360,11564,168
売上成長率(%)-
売上原価18,39616,87116,44616,95416,76814,93413,89112,77513,50914,11215,48513,62617,41116,12615,193
研究開発費10,9918,4678,1687,5037,1806,70410,12410,2089,7529,87213,55812,24513,54830,53117,938
販売管理費13,24513,73312,77611,91111,60610,3139,7629,83010,10210,61510,4689,63410,04210,50410,816
経常(税引前)利益-7,3348,7395,54517,2835,4014,6596,5218,70111,4648,79113,87916,4441,88919,936
経常(税引前)利益率(%)-15.318.512.640.913.711.716.320.624.518.328.527.73.131.1
法人税等合計6719422,4401,0285,3499427184,1032,5081,6871,7091,5211,9181,5122,803
実効税率(%)-
純利益9826,3926,2994,51711,9344,4593,9412,4186,2209,8437,08213,04914,51936517,133
純利益率(%)
一株あたり利益0.282.042.031.494.121.581.420.882.343.842.795.165.730.146.76
希薄化後一株あたり利益0.282.0221.474.071.561.410.872.323.812.785.145.710.146.74
配当性向(%)
一株あたり配当金1.521.561.691.731.771.811.851.891.992.262.482.642.82.963.12